Showing results (11-20 of 61) with videos related to
Sort By:
Pageof 7
Diagnostic Microbiology and Infectious Disease|March 23, 2007
Development of anidulafungin for disk diffusion susceptibility testing against Candida sppRonald N Jones, Jeffrey T Kirby, Shawn A Messer, et al.Journal of Clinical Microbiology|October 26, 2007
Lodderomyces elongisporus masquerading as Candida parapsilosis as a cause of bloodstream infectionsShawn R Lockhart, Shawn A Messer, Michael A Pfaller, et al.Journal of Clinical Microbiology|June 20, 2008
Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosisShawn R Lockhart, Shawn A Messer, Michael A Pfaller, et al.The Journal of Antibiotics|June 30, 2021
Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011-2019)Michael A Pfaller, Cecilia G Carvalhaes, Paul Rhomberg, et al.The Journal of Antimicrobial Chemotherapy|August 30, 2011
Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methodsMichael A Pfaller, Naoaki Watanabe, Mariana Castanheira, et al.Antimicrobial Agents and Chemotherapy|February 5, 2020
Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018)Michael A Pfaller, Cecilia Carvalhaes, Shawn A Messer, et al.Antimicrobial Agents and Chemotherapy|December 1, 2010
Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009Michael A Pfaller, Gary J Moet, Shawn A Messer, et al.Mycopathologia|May 15, 2012
Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programmeMichael A Pfaller, Leah N Woosley, Shawn A Messer, et al.Journal of Clinical Microbiology|September 9, 2011
Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of CandidaMichael A Pfaller, Mariana Castanheira, Daniel J Diekema, et al.International Journal of Antimicrobial Agents|April 26, 2011
Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009)Michael A Pfaller, Shawn A Messer, Gary J Moet, et al.Pageof 7